IL1B and neoplasm: Preclinical studies using renal cell carcinoma mouse models further revealed that combinations of IL-1β inhibitors with anti-PD-1 antibodies or tyrosine kinase inhibitors yielded significantly enhanced anti-tumor responses compared to monotherapeutic approaches [432].